Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective is to evaluate the effect of the treatment with Micardis® or MicardisPlus® on blood pressure. Secondary objectives are the effect of Micardis® / MicardisPlus® on metabolic parameters (triglycerides, cholesterol, blood glucose and HbA1c) in patients with essential hypertension and diabetes mellitus
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with hypertension and diabetes mellitus |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Micardis® | Drug |
| ||
| MicardisPlus® |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in systolic blood pressure (SBP) | Baseline, after 6 months | |
| Change from Baseline in diastolic blood pressure (DBP) | Baseline, afterr 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of efficacy by investigator on a 6-point scale | after 6 months | |
| Assessment of metabolic effect on a 4-point scale | after 6 months | |
| Change from Baseline in laboratory parameters |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with hypertension and diabetes mellitus recruited by cardiologists, nephrologists or diabetologists
Not provided
| ID | Term |
|---|---|
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077333 | Telmisartan |
| C436283 | telmisartan, hydrochlorothiazide drug combination |
| ID | Term |
|---|---|
| D001713 | Biphenyl Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
Metabolic parameters - Triglyceride, total cholesterol, blood glucose and HbA1c |
| Baseline, after 6 months |
| Assessment of tolerability by investigator on a 5-point scale | after 6 months |
| Number of patients with adverse events | up to 6 months |
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |
| D001562 | Benzimidazoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |